<p>Also: (1) Feasibility of patients becoming pregnant while having TKI treatment after having stable disease for at least two years; and (2) Decreased need for allogeneic transplant.</p>

Also: (1) Feasibility of patients becoming pregnant while having TKI treatment after having stable disease for at least two years; and (2) Decreased need for allogeneic transplant.

CML: Hagop Kantarjian on Treating Patients with the T315I Mutation

Oncology Times reports essential clinical news for oncologists, hematologists and other cancer care professionals. Learn more about our award-winning journal!

Share CML: Hagop Kantarjian on Treating Patients with the T315I Mutation

Sign up to save your podcasts

CML: Hagop Kantarjian on Treating Patients with the T315I Mutation

CML: Hagop Kantarjian on Treating Patients with the T315I Mutation

More shows like Oncology Times - OncTimes Talk

Breast Cancer Trials